Intellia Therapeutics Dossier
Qualitative Analysis
Business overview
Intellia Therapeutics, Inc. is a leading clinical-stage biopharmaceutical company focused on developing potentially curative genome editing treatments using CRISPR/Cas9 technology. The company splits its pipeline into two primary modalities: in vivo programs, where CRISPR edits genes directly inside the patient's body, and ex vivo programs, which modify human cells outside the body before reinfusing them. Intellia's lead in vivo candidates include lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z, formerly NTLA-2001) for transthyretin (ATTR) amyloidosis, developed in collaboration with Regeneron Pharmaceuticals.
Research as of 19 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Complete the rolling BLA process for lonvo-z in hereditary angioedema while building launch capabilities. Intellia has finalized field medical, reimbursement and strategic-accounts teams and is engaging U.S. HAE treatment centers.
Expected impact: Advance lonvo-z from a successful Phase 3 program toward regulatory review and potential U.S. commercialization as a one-time outpatient treatment for HAE.
Advance the MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z in ATTR cardiomyopathy and hereditary ATTR polyneuropathy, respectively, following resolution of the clinical holds and resumption of enrollment.
Expected impact: Progress a one-time in vivo CRISPR candidate intended to produce rapid, deep and potentially lifelong reduction of transthyretin protein across two major ATTR disease manifestations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Intellia leads development and commercialization of nex-z in collaboration with Regeneron; the partnership supports the ongoing MAGNITUDE and MAGNITUDE-2 Phase 3 programs.